OC
OCSAW
Oculis Holding AG
$16.43
0.00%
$252.2M
No data for this timeframe.
Vol
Market Cap$252.2M
Cap SizeMicro Cap
SEC Reports2
Recent Activity
Jun 4, 2026
clinical_trial_readout
Results Pending: Dexamethasone ophthalmic suspension (OCS-01) (Phase 3) — Completed 55d ago
Trial: A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular
May 11, 2026
SEC
Oculis reported Q1 2026 results with a net loss of CHF 28.9 million ($36.8M), improved from CHF 33.2 million ($36.9M) in
6-K — Impact 5/10
Apr 21, 2026
SEC
Oculis Holding AG reported a transformative 2025 marked by significant clinical progress across its pipeline, including
6-K — Impact 8/10
Latest Reports
NEUTRAL
6-K
5/10
Oculis reported Q1 2026 results with a net loss of CHF 28.9 million ($36.8M), improved from CHF 33.2 million ($36.9M) in
May 11, 2026
BULLISH
6-K
8/10
Oculis Holding AG reported a transformative 2025 marked by significant clinical progress across its pipeline, including
Apr 21, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 6.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | -34.8% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | -29.8% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | -31.4% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 862.9% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
Clinical Trial
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
Phase Phase 3 — COMPLETED
Jun 4, 2026
clinical_trial_readout
Results Pending: Dexamethasone ophthalmic suspension (OCS-01) (Phase 3) — Completed 55d ago
Trial: A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
Sponsor: Oculis
Phase: Phase 3
May 31, 2026
Clinical Trial
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
Phase Phase 3 — COMPLETED
May 31, 2026
clinical_trial_readout
Results Pending: Dexamethasone ophthalmic suspension (OCS-01) (Phase 3) — Completed 59d ago
Trial: A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
Sponsor: Oculis
Phase: Phase 3
May 5, 2026
clinical_trial_readout
Results Pending: Dexamethasone ophthalmic suspension (OCS-01) (Phase 3) — Completed 25d ago
Trial: A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
Sponsor: Oculis
Phase: Phase 3
May 1, 2026
clinical_trial_readout
Results Pending: Dexamethasone ophthalmic suspension (OCS-01) (Phase 3) — Completed 29d ago
Trial: A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
Sponsor: Oculis
Phase: Phase 3